Author:
Kundadka Varnika,Vatsa Radha,Kaur Navrinder
Abstract
AbstractThis study aimed to identify the prognostic signature of p16INK4a and related genes in non-small cell lung cancer (NSCLC). Since non-small cell lung cancer shows a poor prognosis, the 5-year survival rate in advanced stages is low. This emphasizes the need to identify more reliable diagnostic biomarkers for the early diagnosis of NSCLC and understand the molecular mechanisms underlying the progression of the disease. The role of P16 in essential cellular pathways are still unknown. Understanding its function and the mechanisms underlying its dysregulation could potentially lead to the development of targeted therapies for certain cancers. To address this, bioinformatics analyses revealed differential expression of genes in lung tumour tissues vs control samples. The interactions among the identified DEGs can help better understand the underlying molecular mechanism of NSCLC. We investigated the correlation between p16INK4a expression and genes involved in the relevant interactive pathways in early-stage NSCLC. These can serve as potential diagnostic and therapeutic biomarkers for NSCLC.
Publisher
Cold Spring Harbor Laboratory
Reference34 articles.
1. Alberts, B. , Johnson, A. , Lewis, J. , Raff, M. , Roberts, K. , & Walter, P. (2002). Integrins. https://www.ncbi.nlm.nih.gov/books/NBK26867/
2. Hypoxia in Lung Cancer Management: A Translational Approach
3. Epigenetics in non-small cell lung cancer: from basics to therapeutics
4. Phosphorylation of the Retinoblastoma protein (Rb) on serine-807 is required for association with Bax
5. The history and future of targeting cyclin-dependent kinases in cancer therapy